Financial Data and Key Metrics Changes - The company recorded revenue of $3.4 million in Q1 2025, down from $3.8 million in the same period of 2024, attributed to capital budget impacts from certain inpatient rehabilitation facilities related to the EksoNR enterprise health product [7] - Gross profit for Q1 was $1.8 million, representing a gross margin of approximately 54%, compared to a gross profit of $2 million and a gross margin of 52% for Q1 2024 [8] - Operating expenses for Q1 2025 were $5.3 million, essentially unchanged from $5.2 million in Q1 2024 [8] - The net loss applicable to common stockholders for Q1 2025 was $2.9 million, or $0.12 per share, compared to a net loss of $3.4 million, or $0.20 per share, in Q1 2024 [8] - As of March 31, 2025, the company had cash and restricted cash of $8.1 million, up from $6.5 million at the end of 2024 [9] Business Line Data and Key Metrics Changes - The primary end market for the company's exoskeleton technology is healthcare, with two segments: enterprise health and personal health [6] - The legacy enterprise health products, mainly the EksoNR device, faced revenue declines due to budget impacts, while the Ekso Indigo personal device saw good growth [10] - The company developed a pipeline of over 35 Medicare beneficiaries qualified for the Ekso Indigo Personal in 2025, a 37% increase from the previous quarter [12] Market Data and Key Metrics Changes - The company experienced softness in the legacy enterprise business in Q1 due to customers' capital budgets being impacted by macroeconomic uncertainties [10] - There is a strong pipeline in the enterprise business, but budget constraints have temporarily affected purchases [27] Company Strategy and Development Direction - The company is focusing on building a scalable go-to-market strategy for the Ekso Indigo Personal, leveraging partnerships with distribution networks [14] - The engagement with Priya Healthcare and the addition of Bionic P and O as distributors are expected to broaden access to the Ekso Indigo Personal device [15] - The company anticipates that the majority of revenue in 2025 will still come from enterprise health, but expects increasing contributions from personal health products [15] Management's Comments on Operating Environment and Future Outlook - Management noted that while there is uncertainty in capital budgets, they expect solid contributions from enterprise health in 2025 due to upcoming renewals [26] - The company is preparing for potential longer-term impacts from budget constraints but remains optimistic about its pipeline and market access capabilities [27] - Management believes that gross margins can improve as revenues expand, supported by effective cost controls [29] Other Important Information - The company operates as one reportable segment with a focus on healthcare, specifically targeting individuals with physical disabilities [6] - The management team emphasized the importance of navigating the complexities of coding, coverage, and payment to enhance access to their products [13] Q&A Session Summary Question: How should investors think about where the patients will fall this year in terms of the Indigo Personal? - Management expects that enterprise products will represent 75% to 80% of the business, with solid contributions from personal products growing quarter over quarter [19] Question: Any more color on how things are going with claims submissions? - Management has learned from past claims and believes they have a strong understanding of what constitutes a successful claim, although definitive criteria from CMS are still pending [23][24] Question: What is the outlook on capital budgeting from IDNs? - Management noted softness in capital budgets in Q1 but expects solid contributions from renewals in 2025 [26][27] Question: Can gross margins continue to improve? - Management believes that with effective cost controls and increased volume, gross margins can improve as revenues expand [29]

Financial Data and Key Metrics Changes - The company recorded revenue of $3.4 million in Q1 2025, down from $3.8 million in Q1 2024, attributed to capital budget impacts from certain inpatient rehabilitation facilities related to the EksoNR enterprise health product [7] - Gross profit for Q1 was $1.8 million, representing a gross margin of approximately 54%, compared to a gross profit of $2 million and a gross margin of 52% for the same period in 2024 [8] - Operating expenses for Q1 2025 were $5.3 million, essentially unchanged from $5.2 million in Q1 2024 [9] - Net loss applicable to common stockholders for Q1 2025 was $2.9 million or $0.12 per share, compared to a net loss of $3.4 million or $0.20 per share in Q1 2024 [9] - Cash and restricted cash as of March 31, 2025, was $8.1 million, up from $6.5 million at the end of 2024 [10] Business Line Data and Key Metrics Changes - The enterprise health segment saw a reduction in revenue, while the Ekso Indigo Personal experienced good growth, indicating a shift in revenue contributions [11] - The company has developed a pipeline of over 35 Medicare beneficiaries qualified for the Ekso Indigo Personal in 2025, a 37% increase from the previous quarter [13] Market Data and Key Metrics Changes - The company noted softness in the legacy enterprise business due to capital budget impacts from customers reacting to macroeconomic uncertainties [11] - The regulatory change by CMS in Q2 2024 created significant opportunities for the Ekso Indigo Personal, removing barriers for Medicare enrollees with spinal cord injuries [11] Company Strategy and Development Direction - The company is focusing on building a scalable go-to-market strategy for the Ekso Indigo Personal, leveraging partnerships with Priya Healthcare and Bionic P and O to enhance market access [12][14] - The majority of revenue in 2025 is expected to still come from enterprise health, but significant contributions from personal health products are anticipated as the year progresses [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growing pipeline of Medicare beneficiaries and the potential for increased contributions from personal health products throughout 2025 [17] - There are concerns about the impact of economic uncertainties on capital budgets, particularly for inpatient rehabilitation facilities, which could affect future sales [27] Other Important Information - The company has engaged with National Seating and Mobility as an exclusive distributor for the Ekso Indigo Personal within the U.S. Complex Rehabilitation Technology industry [14] - The partnerships with distribution networks are expected to enhance the company's ability to process claims and improve operational efficiency [39][41] Q&A Session Summary Question: How should investors think about where the patients will fall this year in terms of the Indigo Personal? - Management expects that enterprise products will represent 75% to 80% of the business, with solid contributions from personal products growing quarter over quarter [20] Question: Any more color on how things are going with claims submissions? - Management believes they have a strong understanding of what constitutes a solid claim and that current submissions have a high probability of success [24] Question: What is the outlook on capital budgeting from IDNs? - Management noted that while there was softness in Q1, they expect solid contributions from IDNs in 2025 as many renewals are on track [26] Question: Is the current gross margin a new baseline? - Management believes that with continued operational improvements, gross margins can be maintained or improved as revenues expand [29]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-0367049 ...

Exhibit 99.1 Ekso Bionics Announces First Quarter 2025 Financial Results SAN RAFAEL, Calif., May 5, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments "Over the past few weeks, we have significantly expanded access to Ekso Indego Personal via potentially transformative ...

Core Viewpoint - Ekso Bionics Holdings, Inc. reported its financial results for the first quarter of 2025, highlighting a decrease in revenue primarily due to lower sales of legacy devices, while also noting significant partnerships that may enhance future growth in the Personal Health products segment [1][4][11]. Financial Performance - The company recorded revenue of $3.4 million for the quarter ended March 31, 2025, down from $3.8 million in the same period in 2024, mainly due to lower sales of legacy EksoNR devices, although sales of Ekso Indego Personal devices increased [4]. - Gross profit for the first quarter was $1.8 million, with a gross margin of approximately 53.5%, compared to $2.0 million and a gross margin of 51.9% in the prior year, driven by cost savings in the supply chain [5]. - Sales and marketing expenses decreased to $1.7 million from $1.8 million year-over-year, attributed to lower headcount and travel expenses [6]. - Research and development expenses were $1.0 million, down from $1.1 million in the previous year, mainly due to reduced use of product development consultants [7]. - General and administrative expenses increased to $2.6 million from $2.3 million, primarily due to an impairment loss of an intangible asset and higher legal and audit costs [8]. - The net loss applicable to common stockholders was $2.9 million, or $0.12 per share, compared to a net loss of $3.4 million, or $0.20 per share, in the same quarter of 2024 [9]. Cash Flow and Position - The company used $2.0 million of net cash in operations for the first quarter of 2025, a decrease from $3.5 million in the same period in 2024 [9]. - As of March 31, 2025, the company had cash and restricted cash totaling $8.1 million, an increase from $6.5 million at the end of 2024 [9][16]. Strategic Partnerships - Ekso Bionics has formed partnerships with National Seating & Mobility (NSM) and Bionic Prosthetics & Orthotics Group (Bionic P&O), which are expected to enhance access to the Ekso Indego Personal device in the complex rehabilitation technology and orthotics and prosthetics markets, respectively [3][11].

Core Insights - Ekso Bionics Holdings, Inc. is set to release its financial and business results for Q1 2025 on May 5, 2025, after market close [1] - A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and recent business developments [1] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility in both medical and industrial applications [3] - The company focuses on improving health and quality of life through advanced robotics that restore and amplify human function [3] - Ekso Bionics is unique in offering technologies that assist individuals with paralysis to stand and walk, as well as enhancing capabilities in various job sites globally [3] - The company is headquartered in the San Francisco Bay Area and is publicly traded on the Nasdaq under the symbol "EKSO" [3]

Core Insights - Ekso Bionics Holdings, Inc. has appointed Bionic Prosthetics & Orthotics Group LLC as a non-exclusive distributor for its Ekso Indego® Personal device, enhancing its market reach in the orthotics and prosthetics industry [1][3] Company Overview - Ekso Bionics is a leader in exoskeleton technology, focusing on medical and industrial applications, with a mission to improve health and quality of life through advanced robotics [4] - The company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO" [4] Product Details - The Ekso Indego Personal is a lightweight, portable lower extremity powered exoskeleton designed for individuals with spinal cord injuries, enabling them to stand and walk independently [2] - It features a modular quick connect design for ease of use, allowing users to put on and take off the device without assistance [2] - The device has shown to help users achieve faster walking speeds, enhancing their independence in the community [2] Strategic Partnership - The collaboration with Bionic P&O is seen as a strategic move to leverage their expertise in the orthotics and prosthetics market, which is crucial for the successful marketing and distribution of the Ekso Indego Personal [3] - Bionic P&O, founded in 2007, operates across 12 states and is fully accredited, employing certified practitioners in various specialties [5] Market Impact - The partnership aims to empower individuals with spinal cord injuries to pursue their goals of walking again, potentially transforming the orthotics and prosthetics industry [3]

Alliance marks Ekso Bionics’ first entrance into the O&P spaceSAN RAFAEL, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has named Bionic Prosthetics & Orthotics Group LLC (“Bionic P&O”), a leading national provider of prosthetic and orthotic solutions, as a non-exclusive Ekso Indego® Personal device distributor. Ekso Indego Personal is a wearable lower ...

Financial Data and Key Metrics Changes - The company recorded revenue of $5.1 million in Q4 2024, an increase of 5% compared to $4.8 million in Q4 2023 [13] - Gross profit for Q4 was $2.7 million, representing a gross margin of approximately 53%, up from a gross profit of $2.4 million and a gross margin of 49% in Q4 2023 [13] - Operating expenses for Q4 2024 were $4.9 million, a 15% decrease from $5.8 million in Q4 2023 [14] - Net loss applicable to common stockholders for Q4 was $3.4 million or $0.14 per share, compared to a net loss of $3.2 million or $0.22 per share in Q4 2023 [14] - Full year 2024 revenue was $17.9 million, down from $18.3 million in 2023 [15] - Full year gross profit was $9.5 million with a gross margin of approximately 53%, compared to $9.1 million and a gross margin of 50% in 2023 [17] - Full year net loss was $11.3 million or $0.56 per share, compared to a net loss of $15.2 million or $1.10 per share in 2023 [19] Business Line Data and Key Metrics Changes - The primary revenue source is from the sale and subscription of the Ekso NR device and the Ekso Indigo therapy device [10] - The company is focusing on expanding the personal health product line, particularly the Ekso Indigo Personal, which is expected to contribute to revenue growth starting in 2025 [31] Market Data and Key Metrics Changes - The company is experiencing growth in the APAC region, particularly with the Ekso NR and Indigo therapy devices [42] - Exceptional growth was noted in Europe, especially within the French hospital systems [44] Company Strategy and Development Direction - The company is shifting its focus to a scalable go-to-market strategy for the Ekso Indigo Personal, supported by partnerships with reimbursement services and market access firms [25][30] - Engaging Priya Healthcare for reimbursement services is seen as a critical move to navigate the complexities of Medicare claims [28] - The company aims to broaden access to the Ekso Indigo Personal through partnerships with National Seating and Mobility and other durable medical equipment suppliers [29][72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in securing multi-unit orders in 2025 as procurement cycles return to normal for larger institutions [38] - The company anticipates meaningful growth in claims submissions for Medicare beneficiaries in 2025, with a current pipeline of about twenty-five individuals [39] - Management is optimistic about the overall commercial traction expected in both enterprise and personal markets in 2025 [76] Other Important Information - The company had cash and restricted cash of $6.5 million as of December 31, 2024 [19] Q&A Session Summary Question: Confidence in securing multi-unit orders and volume of Indigo claims - Management expects more multi-unit orders in 2025 and plans to submit claims for about twenty-five individuals this year [38][39] Question: Growth trajectory in Europe and APAC regions - Management projects continued growth in APAC and a return to normal growth rates in Europe after exceptional growth in 2024 [42][44] Question: Patient interest generated via marketing activities - A large number of leads are being processed, with a focus on individuals with spinal cord injuries who meet health requirements [50] Question: Relationship with National Seating and Mobility - The partnership aims to leverage NSM's expertise in the complex rehabilitation technology industry to enhance distribution and reimbursement processes [70]

Product Development and Market Strategy - The company designs, develops, and markets exoskeleton products primarily for the healthcare sector, targeting individuals with physical disabilities [14]. - The company operates in two markets: Enterprise Health and Personal Health, generating revenue through device sales and subscription services [24]. - The company continues to explore business development initiatives to fuel growth and long-term value through technology and advanced rehabilitative programs [15]. - The company is developing a scalable go-to-market strategy by building relationships with national and regional Durable Medical Equipment suppliers (DMEs) [36]. - The company aims to expand insurance coverage beyond CMS and seek additional indications of use for its products, which could drive significant growth [36]. - The company continues to invest in research and development to enhance product offerings in the exoskeleton market, responding to evolving demands [121]. Regulatory and Compliance Challenges - The company is subject to various foreign regulations governing clinical trials and commercial sales, which vary significantly by country [65]. - Regulatory compliance costs may increase due to potential changes in FDA policies and foreign regulatory authorities, impacting product approval timelines [71]. - The process of obtaining FDA approval for medical devices can take from several months to over a year for 510(k) clearance and from one to three years or longer for PMA, with PMA generally requiring clinical trials [162]. - Non-compliance with regulatory requirements can lead to severe sanctions, including product recalls, fines, and suspension of manufacturing operations [165]. - The FDA's new QMSR will be enforced starting February 2, 2026, replacing the existing QSR, which may increase compliance costs and operational disruptions [183]. - The company must report adverse events and production problems to the FDA and may face significant penalties for non-compliance with post-market regulatory requirements [169]. Financial Performance and Funding - The company has incurred significant losses to date and anticipates continuing to incur losses in the future, raising concerns about achieving profitability [102]. - The company has significant cash outlays required to support operations and remains largely dependent on capital raised from past and future financings to implement its business plan [139]. - As of December 31, 2024, the company had cash and restricted cash of $6.5 million, which is not sufficient to fund operations for the next 12 months without substantial revenue increases [146]. - The company is seeking additional financing and evaluating alternatives to meet cash requirements for the next 12 months, with uncertainty regarding the availability of such capital [147]. - The company’s current sales and marketing, research and development, and general and administrative expenses are higher as a percentage of sales than needed for profitability, which may hinder margin improvement [148]. Market Opportunities and Reimbursement - In April 2024, CMS approved a reimbursement payment level of approximately $91,000 for the Ekso Indego Personal, effective April 1, 2024, potentially increasing demand among Medicare enrollees with spinal cord injuries (SCI) [36]. - Approximately 57% of individuals with SCI are enrolled in Medicare or Medicaid within five years post-injury, indicating a significant market opportunity for the Ekso Indego Personal [36]. - The reimbursement policy allows individual users who meet FDA-approved indications to purchase the Ekso Indego Personal through authorized DMEs and receive 80% reimbursement of the applicable rate [43]. - The company has faced challenges in the reimbursement process for its Personal Health products, with the first CMS reimbursement claim submitted in May 2024 and reimbursed in July 2024 [104]. - The company anticipates submitting approximately 25 claims for reimbursement to CMS over the next six to nine months [104]. Competition and Market Position - The company faces competition in the medical technology and industrial robotics industries, particularly in exoskeleton technology, which is still in its early stages [72]. - For Enterprise Health products, competition primarily comes from traditional non-robotic therapy by licensed physical therapists and other mechanical or robotic therapy devices [73]. - Personal Health products compete mainly with manual or powered wheelchairs and other traditional mobility aids, with clinical evidence supporting better outcomes for certain users [74]. - The commercial success of the company’s products will depend on adequate reimbursement levels established by governmental and private payers [60]. Intellectual Property and Licensing - The company has established an extensive intellectual property portfolio with 77 issued U.S. patents and 5 pending applications as of December 31, 2024 [81]. - The patent portfolio includes technologies relevant to medical and commercial exoskeletons, with the earliest priority date reaching back to 2003 [83]. - The company entered a license agreement with Vanderbilt University, paying a $100,000 fee and agreeing to royalties of 3.75% on net sales, with minimum annual royalties starting at $75,000 in 2027 [90]. Operational Risks and Challenges - Supply chain disruptions and material shortages, particularly in electronic components and battery cells, may negatively impact the company's future results [112][113]. - The company faces intense competition in the medical devices and industrial robotics markets, which may affect its market position and financial performance [106]. - Future trade policies and potential tariff increases may require the company to adjust sourcing strategies, which could incur substantial costs and operational challenges [114]. - The company faces challenges in reducing manufacturing costs and maintaining high service standards for its products [137]. Employee and Workforce Relations - As of February 28, 2025, the company had 61 full-time employees and five part-time employees, with a good relationship with its workforce [97].